NocitaTM — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

NocitaTM

Active ingredient

Bupivacaine

Application type

NADA

Sponsor

Elanco US Inc.

Applications on record

1

First published

March 2, 2021

Adverse event reports

Source: openFDA VeDDRA

627

Reports mentioning this ingredient

February 20, 2012 – March 16, 2026

189

Classified serious

per reporter assessment

21

Lack of expected efficacy

resistance signal

3

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “BUPIVACAINE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Vials, Damaged	37
Bruising	23
Stopper, abnormal	21
Injection site bruising	18
Containers, Damaged	17
Injection site swelling	15
Injection site infection	13
Product Defect, General	13
Surgical site disorder	13
Swelling NOS	12
Lack of efficacy - NOS	11
Caps, Abnormal	11
Bacterial skin infection NOS	10
Vials, Leaking	10
Incorrect storage of drug	9
Dehiscence	9
Death	9
Vials, Abnormal	9
Other abnormal test result NOS	8
Contamination, Particulate Matter	8

Species affected

Source: openFDA VeDDRA

Cat 232 Dog 223 Human 12 Rabbit 2 Pig 2 Horse 1 Rat 1 Cephalopoda 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient